Vienna Powszechne Towarzystwo Emerytalne S.A. Vienna Insurance Group Sells 2,337 Shares of Medtronic PLC $MDT

Vienna Powszechne Towarzystwo Emerytalne S.A. Vienna Insurance Group cut its stake in Medtronic PLC (NYSE:MDT) by 19.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,875 shares of the medical technology company’s stock after selling 2,337 shares during the period. Vienna Powszechne Towarzystwo Emerytalne S.A. Vienna Insurance Group’s holdings in Medtronic were worth $861,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in MDT. Brighton Jones LLC boosted its holdings in Medtronic by 1,368.0% in the fourth quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock valued at $3,194,000 after acquiring an additional 37,265 shares during the last quarter. GAMMA Investing LLC boosted its holdings in Medtronic by 41.1% in the first quarter. GAMMA Investing LLC now owns 15,882 shares of the medical technology company’s stock valued at $1,427,000 after acquiring an additional 4,626 shares during the last quarter. Perigon Wealth Management LLC boosted its holdings in Medtronic by 7.5% in the first quarter. Perigon Wealth Management LLC now owns 13,735 shares of the medical technology company’s stock valued at $1,234,000 after acquiring an additional 953 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Medtronic by 11.5% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 156,185 shares of the medical technology company’s stock valued at $13,686,000 after acquiring an additional 16,136 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its holdings in Medtronic by 8.3% in the first quarter. Allspring Global Investments Holdings LLC now owns 1,149,116 shares of the medical technology company’s stock valued at $101,685,000 after acquiring an additional 87,711 shares during the last quarter. 82.06% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

MDT has been the topic of several analyst reports. Royal Bank Of Canada reiterated an “outperform” rating and issued a $111.00 target price on shares of Medtronic in a report on Friday, October 10th. Needham & Company LLC restated a “hold” rating on shares of Medtronic in a report on Thursday, August 14th. William Blair upgraded Medtronic to a “hold” rating in a report on Friday, July 11th. BTIG Research restated a “neutral” rating on shares of Medtronic in a report on Friday, July 11th. Finally, UBS Group increased their price target on Medtronic from $94.00 to $95.00 and gave the stock a “neutral” rating in a report on Wednesday, August 20th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Medtronic has a consensus rating of “Moderate Buy” and an average price target of $102.82.

Insider Buying and Selling at Medtronic

In other Medtronic news, EVP Harry Skip Kiil sold 8,605 shares of the company’s stock in a transaction on Wednesday, September 3rd. The shares were sold at an average price of $91.58, for a total transaction of $788,045.90. Following the transaction, the executive vice president owned 35,615 shares in the company, valued at approximately $3,261,621.70. This represents a 19.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director William R. Jellison acquired 2,500 shares of the stock in a transaction on Monday, August 25th. The shares were acquired at an average price of $92.37 per share, for a total transaction of $230,925.00. Following the acquisition, the director owned 5,000 shares of the company’s stock, valued at approximately $461,850. The trade was a 100.00% increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 0.26% of the company’s stock.

Medtronic Price Performance

Shares of MDT opened at $93.76 on Monday. The business’s fifty day moving average is $94.32 and its 200 day moving average is $89.42. Medtronic PLC has a 12-month low of $79.29 and a 12-month high of $99.37. The company has a quick ratio of 1.50, a current ratio of 2.01 and a debt-to-equity ratio of 0.54. The stock has a market cap of $120.26 billion, a P/E ratio of 25.83, a P/E/G ratio of 2.47 and a beta of 0.78.

Medtronic (NYSE:MDT) last released its quarterly earnings data on Tuesday, August 19th. The medical technology company reported $1.26 earnings per share for the quarter, topping the consensus estimate of $1.23 by $0.03. Medtronic had a net margin of 13.63% and a return on equity of 14.61%. The firm had revenue of $8.58 billion for the quarter, compared to the consensus estimate of $8.37 billion. During the same quarter in the prior year, the company posted $1.23 earnings per share. The business’s revenue was up 7.7% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. Sell-side analysts anticipate that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, October 17th. Shareholders of record on Friday, September 26th were issued a dividend of $0.71 per share. The ex-dividend date was Friday, September 26th. This represents a $2.84 annualized dividend and a yield of 3.0%. Medtronic’s dividend payout ratio is presently 78.24%.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.